The estimated Net Worth of Francesco Micheli is at least $465 Milion dollars as of 13 August 2020. Francesco Micheli owns over 1,500,000 units of Intercept Pharmaceuticals Inc stock worth over $76,000,000 and over the last 11 years Francesco sold ICPT stock worth over $389,440,658.
Francesco has made over 7 trades of the Intercept Pharmaceuticals Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Francesco sold 1,500,000 units of ICPT stock worth $71,250,000 on 13 August 2020.
The largest trade Francesco's ever made was selling 1,500,000 units of Intercept Pharmaceuticals Inc stock on 13 August 2020 worth over $71,250,000. On average, Francesco trades about 690,550 units every 356 days since 2013. As of 13 August 2020 Francesco still owns at least 4,000,000 units of Intercept Pharmaceuticals Inc stock.
You can see the complete history of Francesco Micheli stock trades at the bottom of the page.
Francesco's mailing address filed with the SEC is Via Privata Giovannino De Grassi, 11, 20123 Milano MI, Italy.
Over the last 12 years, insiders at Intercept Pharmaceuticals Inc have traded over $1,530,243,701 worth of Intercept Pharmaceuticals Inc stock and bought 2,408,920 units worth $77,118,364 . The most active insiders traders include Srinivas Akkaraju, Jonathan Silverstein a Francesco Micheli. On average, Intercept Pharmaceuticals Inc executives and independent directors trade stock every 10 days with the average trade being worth of $1,114,673. The most recent stock trade was executed by Srinivas Akkaraju on 10 March 2021, trading 237,000 units of ICPT stock currently worth $5,017,290.
we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.
Intercept Pharmaceuticals Inc executives and other stock owners filed with the SEC include: